Clinical responses with T lymphocytes targeting malignancy-associated κ light chains-Reference-Cited by-同舟云学术

Clinical responses with T lymphocytes targeting malignancy-associated κ light chains

Published:2016-06-06 Issue:7 Volume:126 Page:2588-2596
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Ramos Carlos A.,Savoldo Barbara,Torrano Vicky,Ballard Brandon,Zhang Huimin,Dakhova Olga,Liu Enli,Carrum George,Kamble Rammurti T.,Gee Adrian P.,Mei Zhuyong,Wu Meng-Fen,Liu Hao,Grilley Bambi,Rooney Cliona M.,Brenner Malcolm K.,Heslop Helen E.,Dotti Gianpietro

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference29 articles.

1. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

2. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia;Brentjens;Sci Transl Med,2013

3. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia;Davila;Sci Transl Med,2014

4. Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

5. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Cited by 250 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Prolonged cytopenias after immune effector cell therapy and lymphodepletion in patients with leukemia, lymphoma and solid tumors;Cytotherapy;2024-09

3. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

4. CD19 CAR T cells for B cell malignancies: a systematic review and meta-analysis focused on clinical impacts of CAR structural domains, manufacturing conditions, cellular product, doses, patient’s age, and tumor types;BMC Cancer;2024-08-22

5. Targeting cancer stem cells in multiple myeloma;Trends in Cancer;2024-08